We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

5 hedge funds and large institutions have $574K invested in Loncar China BioPharma ETF in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more capital invested

Capital invested by funds: $411K → $574K (+$163K)

25% more funds holding

Funds holding: 4 → 5 (+1)

0.64% more ownership

Funds ownership: 9.55% → 10.2% (+0.64%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$49K
2
TRCT
Tower Research Capital (TRC)
New York
+$33

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$14.4K
2
BBPWM
Blue Bell Private Wealth Management
Pennsylvania
-$2.36K

CHNA Hedge Fund Activity: Q4 2022 in Review

5 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q4 2022, worth a combined $574K — up 40% from $411K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new CHNA positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Jane Street, adding an estimated $49K. The largest seller was UBS Group, cutting an estimated $14.4K.

  • 5 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q4 2022, up from 4 in Q3 2022.
  • Funds reported $574K of Loncar China BioPharma ETF stock for Q4 2022, up 40% quarter-over-quarter.
  • 1 fund opened new Loncar China BioPharma ETF positions in Q4 2022 and 0 closed out, a net change of +1 holder.
  • The largest Loncar China BioPharma ETF buyer in Q4 2022 was Jane Street, an estimated $49K added.
  • The largest Loncar China BioPharma ETF seller in Q4 2022 was UBS Group, an estimated $14.4K sold.

Based on aggregated 13F filings for Q4 2022.